Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 371.30M +188.7% |
| Revenue (ttm) | n/a |
| Net Income | -19.48M |
| EPS | -1.46 |
| Shares Out | 13.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,044 |
| Open | 29.34 |
| Previous Close | 28.99 |
| Day's Range | 26.65 - 29.38 |
| 52-Week Range | 7.78 - 34.10 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 47.50 (+77.24%) |
| Earnings Date | Jun 2, 2026 |
About GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breas... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GLSI stock is "Strong Buy." The 12-month stock price target is $47.5, which is an increase of 77.24% from the latest price.
News
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinic...
Greenwich LifeSciences says Form 10-K ‘still being audited’
Greenwich LifeSciences (GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025…
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences receives noncompliance notification from Nasdaq
Greenwich LifeSciences announced that on April 16, the company received notification from Nasdaq notifying the company that, because it has not yet filed its annual report on Form 10-K for…
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026
Greenwich LifeSciences (GLSI) focused on its Phase III clinical trial, FLAMINGO-01 presents the published abstract and poster from the AACR Meeting 2026. This is the first abstract and poster presente...
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences reports cash balance of $10.5M as of March 31
Greenwich LifeSciences (GLSI) provided additional updates on its financing strategy. The company’s ATM financing vehicle allows the company to sell its common stock directly into the trading market at...
Greenwich LifeSciences Provides Update on Financing Strategy
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01
Greenwich LifeSciences (GLSI) provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data. Statistically significant immu...
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial
Greenwich LifeSciences (GLSI) announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest…
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences provides update on presentations at AACR Meeting 2026
Greenwich LifeSciences (GLSI) provided an update on the upcoming AACR Meeting 2026. Two abstracts and two posters were accepted for presentation. On April 20, 2-5pm Greenwich will present a Preliminar...
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial
Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, provided a preliminary update ...
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01
STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01
Greenwich LifeSciences (GLSI) provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01. The Company previously announced that the first three commercial lots of GP2 act...
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial
Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, provided...
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial
Greenwich LifeSciences (GLSI) provided additional updates on its cash burn rate and financing strategy for its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100...
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...